Dexmedetomidine Kalceks 100 mikrogram/ml Koncentrat till infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dexmedetomidine kalceks 100 mikrogram/ml koncentrat till infusionsvätska, lösning

as kalceks - dexmedetomidinhydroklorid - koncentrat till infusionsvätska, lösning - 100 mikrogram/ml - dexmedetomidinhydroklorid 118 mikrog aktiv substans

Diprivan 20 mg/ml Injektionsvätska/infusionsvätska, emulsion Sverige - svenska - Läkemedelsverket (Medical Products Agency)

diprivan 20 mg/ml injektionsvätska/infusionsvätska, emulsion

abboxia ab - propofol - injektionsvätska/infusionsvätska, emulsion - 20 mg/ml - propofol 20 mg aktiv substans; sojaolja, raffinerad hjälpämne; glycerol hjälpämne

Dexmedetomidine B. Braun 100 mikrogram/ml Koncentrat till infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dexmedetomidine b. braun 100 mikrogram/ml koncentrat till infusionsvätska, lösning

b. braun melsungen ag - dexmedetomidinhydroklorid - koncentrat till infusionsvätska, lösning - 100 mikrogram/ml - dexmedetomidinhydroklorid 118 mikrog aktiv substans

Dexmedetomidine Baxter 100 mikrogram/ml Koncentrat till infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dexmedetomidine baxter 100 mikrogram/ml koncentrat till infusionsvätska, lösning

baxter holding b.v. - dexmedetomidinhydroklorid - koncentrat till infusionsvätska, lösning - 100 mikrogram/ml - dexmedetomidinhydroklorid 118 mikrog aktiv substans

Jayempi Europeiska unionen - svenska - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - graftförkastning - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Dexmedetomidine Kabi 100 mikrogram/ml Koncentrat till infusionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dexmedetomidine kabi 100 mikrogram/ml koncentrat till infusionsvätska, lösning

fresenius kabi ab - dexmedetomidinhydroklorid - koncentrat till infusionsvätska, lösning - 100 mikrogram/ml - dexmedetomidinhydroklorid 118 mikrog aktiv substans

Desflurane Baxter 100 % Inhalationsånga, vätska Sverige - svenska - Läkemedelsverket (Medical Products Agency)

desflurane baxter 100 % inhalationsånga, vätska

baxter medical ab - desfluran - inhalationsånga, vätska - 100 % - desfluran 1 ml aktiv substans

Fenantoin RPH Pharma 100 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fenantoin rph pharma 100 mg tablett

rph pharmaceuticals ab - fenytoin - tablett - 100 mg - laktosmonohydrat hjälpämne; fenytoin 100 mg aktiv substans - fenytoin

Lehydan 100 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lehydan 100 mg tablett

leyh pharma gmbh - fenytoin - tablett - 100 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; fenytoin 100 mg aktiv substans; glycerol hjälpämne - fenytoin

Lehydan 25 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lehydan 25 mg tablett

leyh pharma gmbh - fenytoin - tablett - 25 mg - natriumlaurilsulfat hjälpämne; glycerol hjälpämne; fenytoin 25 mg aktiv substans; laktosmonohydrat hjälpämne - fenytoin